Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17‐1A (Q40589131)

From Wikidata

Jump to navigation Jump to search

scientific article published on July 10, 2003

Language	Label	Description	Also known as
English	Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17‐1A	scientific article published on July 10, 2003

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17‐1A (English)

reason for preferred rank

most precise value

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740924

1 January 2024

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

Jan-Erik Frodin

6

object named as

Jan-Erik Frödin

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740924

1 January 2024

author name string

Maria Liljefors

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Bo Nilsson

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Anna-Lena Hjelm Skog

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Peter Ragnhammar

4

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Håkan Mellstedt

5

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

language of work or name

0 references

publication date

1 July 2003

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

10 July 2003

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12740924

1 January 2024

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fijc.11139

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.11139

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

105

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

717-723

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11139

21 January 2018

Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11139

21 January 2018

Effect of human blood mononuclear cell populations in antibody dependent cellular cytotoxicity (ADCC) using two murine (CO17-1A and Br55-2) and one chimeric (17-1A) monoclonal antibodies against a human colorectal carcinoma cell line (SW948).

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11139

21 January 2018

Biology of natural killer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11139

21 January 2018

Downregulation of innate and acquired antitumor immunity by bystander gammadelta and alphabeta T lymphocytes with Th2 or Tr1 cytokine profiles

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11139

21 January 2018

Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11139

21 January 2018

Analysis of the relationship between stage of differentiation and NK/LAK susceptibility of colon carcinoma cells.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11139

21 January 2018

The potential for monocyte-mediated immunotherapy during infection and malignancy. Part I: apoptosis induction and cytotoxic mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11139

21 January 2018

Interactions between human monocytes and tumour cells. Monocytes can either enhance or inhibit the growth and survival of K562 cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11139

21 January 2018

Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11139

21 January 2018

Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11139

21 January 2018

NK and NK/T cells in human senescence

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11139

21 January 2018

Natural killing and antibody-dependent cytotoxicity by lymphocyte subpopulations in young and aging humans

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11139

21 January 2018

Age-dependent decline of natural killer and antibody-dependent cell mediated cytotoxicity activity of human lymphocytes is connected with decrease of their acid phosphatase activity.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11139

21 January 2018

Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11139

21 January 2018

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11139

21 January 2018

Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma

1

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells

4

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy

10

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

Prognostic significance of natural killer cell activity in patients with laryngeal carcinoma

11

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

Preoperative natural killer cell activity: correlation with distant metastases in curatively research colorectal carcinomas

12

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

Quantitation of natural killer cell function and risk of metastatic poorly differentiated head and neck cancer

13

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

Cellular immunologic parameters related to age, gender, and stage in lung cancer patients

14

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

Monocyte- and natural killer cell-mediated spontaneous cytotoxicity against human noncultured solid tumor cells

20

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer

25

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

Lymphokine activated killer (LAK) cells in antibody dependent cellular cytotoxicity (ADCC) using MAb 17-1A: a combination of potential usefulness in tumor therapy

27

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced

28

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumour cells

29

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

Increased killer cell activity in aged humans

33

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

Natural killer cells and tumor therapy

34

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

Escape from host-antitumor immunity.

35

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

Natural killer activity in patients with breast cancer

36

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

Natural killing activity is associated with progression of gastric cancer

37

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

A new prognostic classification of rectal cancer

41

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment

45

1 reference

10.1002/IJC.11139

https://api.crossref.org/works/10.1002/IJC.11139

1 January 2024

Identifiers

10.1002/IJC.11139

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40589131&oldid=2042184253"